Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription Articles published in AJR Am J Roentgenol Retrieve available abstracts of 104 articles: HTML format

Single Articles

March 2024
1. GASTOUNIOTI A, Kontos D
   Artificial Intelligence in Breast Imaging Daily Clinical Practice: Point-Reshaping Breast Cancer Screening.
   AJR Am J Roentgenol. 2024 Mar 27. doi: 10.2214/AJR.24.31174.
   PubMed    
   
   
   February 2024
2. PANIGRAHI B
   Editorial Comment: Utilization of Radiomics to Identify HER2-Low Breast Cancer.
   AJR Am J Roentgenol. 2024 Feb 14. doi: 10.2214/AJR.24.30953.
   PubMed    
   
   
   January 2024
3. PENG Y, Zhang X, Qiu Y, Li B, et al
   Development and Validation of MRI Radiomics Models to Differentiate HER2-Zero, -Low, and -Positive Breast Cancer.
   AJR Am J Roentgenol. 2024 Jan 24. doi: 10.2214/AJR.23.30603.
   PubMed     Abstract available
   
   
   
4. GERLACH K
   Editorial Comment: Managing Breast Imaging Follow-Up After a Prior Breast Cancer Diagnosis.
   AJR Am J Roentgenol. 2024 Jan 10. doi: 10.2214/AJR.23.30772.
   PubMed    
   
   
   
5. IGARASHI T
   Editorial Comment: What Is the Utility of T2 Signal Intensity in Patients With HER2-Positive Breast Cancer?
   AJR Am J Roentgenol. 2024 Jan 10. doi: 10.2214/AJR.23.30785.
   PubMed    
   
   
   
6. LANGMAN EL, Johnson KS, Dinome ML
   Retained Biopsy Site Markers After Breast Lesion Surgical Resection: Associations With Residual Malignancy.
   AJR Am J Roentgenol. 2024;222:e2329670.
   PubMed     Abstract available
   
   
   
7. BUTLER RS
   Editorial Comment: Artificial Intelligence May Help Define Screening Strategies in Patients With Dense Breasts.
   AJR Am J Roentgenol. 2024;222:e2330042.
   PubMed    
   
   
   December 2023
8. DO D, Mercaldo S, Bahl M
   Performance Metrics of Screening Digital Breast Tomosynthesis Based on Years Since a Prior Breast Cancer Diagnosis.
   AJR Am J Roentgenol. 2023 Dec 20. doi: 10.2214/AJR.23.30419.
   PubMed     Abstract available
   
   
   
9. JIRARAYAPONG J, Portnow LH, Chikarmane SA, Lan Z, et al
   High Peritumoral and Intratumoral T2 Signal Intensity in HER2+ Breast Cancers on Preneoadjuvant Breast MRI: Assessment of Associations With Histopathologic Characteristics.
   AJR Am J Roentgenol. 2023 Dec 20. doi: 10.2214/AJR.23.30280.
   PubMed     Abstract available
   
   
   
10. NGUYEN DL, Greenwood HI, Rahbar H, Grimm LJ, et al
    Evolving Treatment Paradigms for Low-Risk Ductal Carcinoma In Situ: Imaging Needs.
    AJR Am J Roentgenol. 2023 Dec 13. doi: 10.2214/AJR.23.30503.
    PubMed     Abstract available
    
    
    
11. DONTCHOS BN, Lobbes MBI, Rahbar H
    Reply to "Cost-Effectiveness of Breast Cancer Staging Modalities: Is There a Role for MDCT in Low- and Moderate-Income Countries?".
    AJR Am J Roentgenol. 2023 Dec 6. doi: 10.2214/AJR.23.30619.
    PubMed    
    
    
    
12. BITENCOURT AGV, Felipe VC, Barbosa PNVP
    Cost-Effectiveness of Breast Cancer Staging Modalities: Is There a Role for MDCT in Low- and Moderate-Income Countries?
    AJR Am J Roentgenol. 2023 Dec 6. doi: 10.2214/AJR.23.30480.
    PubMed    
    
    
    
13. GRIMM LJ
    Beyond the AJR: Patient Knowledge About the Risk of Dense Breasts Is Lacking.
    AJR Am J Roentgenol. 2023;221:850.
    PubMed    
    
    
    November 2023
14. CORINES MJ, Sogani J, Hogan MP, Mango VL, et al
    The Role of Contrast-Enhanced Mammography After Cryoablation of Breast Cancer.
    AJR Am J Roentgenol. 2023 Nov 29. doi: 10.2214/AJR.23.30250.
    PubMed     Abstract available
    
    
    
15. CHOU SS
    Editorial Comment: The Time Is Almost Ripe to Mainstream Diffusion in Routine Breast MRI.
    AJR Am J Roentgenol. 2023 Nov 1. doi: 10.2214/AJR.23.30445.
    PubMed    
    
    
    October 2023
16. GULLO RL, Partridge SC, Shin HJ, Thakur SB, et al
    Update on DWI for Breast Cancer Diagnosis and Treatment Monitoring.
    AJR Am J Roentgenol. 2023 Oct 18. doi: 10.2214/AJR.23.29933.
    PubMed     Abstract available
    
    
    
17. MANN RM, Teuwen J
    Beyond the AJR: A Breakthrough in the Use of Artificial Intelligence for Mammography in Screening for Breast Cancer.
    AJR Am J Roentgenol. 2023 Oct 18. doi: 10.2214/AJR.23.30359.
    PubMed    
    
    
    
18. REICHMAN MB, McMahon P, Dwyer M, Chang SJ, et al
    Bleeding Events After Image-Guided Breast Biopsies: Comparison of Patients Temporarily Discontinuing Versus Maintaining Antithrombotic Therapy During Biopsy.
    AJR Am J Roentgenol. 2023;221:438-449.
    PubMed     Abstract available
    
    
    September 2023
19. BARR RG
    Spatial Resolution Versus Contrast Resolution in Breast Ultrasound.
    AJR Am J Roentgenol. 2023 Sep 27:1. doi: 10.2214/AJR.23.29516.
    PubMed    
    
    
    August 2023
20. LAWHN-HEATH C
    Editorial Comment: Closing the Gap-Emerging Role of Estrogen Receptor-Targeted PET in Invasive Lobular Carcinoma.
    AJR Am J Roentgenol. 2023;221:239.
    PubMed    
    
    
    July 2023
21. LEE SE, Yoon JH, Son NH, Han K, et al
    Screening in Patients With Dense Breasts: Comparison of Mammography, Artificial Intelligence, and Supplementary Ultrasound.
    AJR Am J Roentgenol. 2023 Jul 26. doi: 10.2214/AJR.23.29655.
    PubMed     Abstract available
    
    
    
22. BITENCOURT AGV, Barbosa PNVP, Chojniak R
    Expanding Biopsy Options for Suspicious Breast Lesions: CT-Guided Biopsy Using a 3D-Printed Device.
    AJR Am J Roentgenol. 2023 Jul 5:1-2. doi: 10.2214/AJR.23.29421.
    PubMed    
    
    
    
23. WEAVER OO, Kornecki A, Yang WT
    Reply to: "Expanding Biopsy Options for Suspicious Breast Lesions: CT-Guided Biopsy Using a 3D-Printed Device".
    AJR Am J Roentgenol. 2023 Jul 5:2. doi: 10.2214/AJR.23.29476.
    PubMed    
    
    
    June 2023
24. DEIPOLYI AR, Ward RC, Riaz A, Vogl TJ, et al
    Locoregional Therapies for Primary and Metastatic Breast Cancer: AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2023 Jun 28. doi: 10.2214/AJR.23.29454.
    PubMed     Abstract available
    
    
    May 2023
25. PHILPOTTS LE
    Beyond the AJR: Patient Cost-Sharing Adversely Affects Adherence to Downstream Imaging After Mammography Screening.
    AJR Am J Roentgenol. 2023 May 31. doi: 10.2214/AJR.23.29685.
    PubMed    
    
    
    
26. HE P, Chen W, Bai MY, Li J, et al
    Deep Learning-Based Computer-Aided Diagnosis for Breast Lesion Classification on Ultrasound: A Prospective Multicenter Study of Radiologists Without Breast Ultrasound Expertise.
    AJR Am J Roentgenol. 2023 May 24. doi: 10.2214/AJR.23.29328.
    PubMed     Abstract available
    
    
    
27. PHILPOTTS L
    Editorial Comment: Digital Breast Tomosynthesis Helps Optimize Use of BI-RADS Category 3 in Patients With a Personal History of Breast Cancer.
    AJR Am J Roentgenol. 2023 May 3. doi: 10.2214/AJR.23.29547.
    PubMed    
    
    
    
28. KIETURAKIS AJ, Hernandez OJ, Gao Y
    Mammary Adenoid Cystic Carcinoma: Improving Preoperative Size Assessment With MRI.
    AJR Am J Roentgenol. 2023 May 3. doi: 10.2214/AJR.23.29272.
    PubMed    
    
    
    April 2023
29. DONTCHOS BN, Rahbar H
    Cost-Effectiveness of Breast Cancer Staging Modalities: Counterpoint-Breast MRI Can be Cost-Effective for Breast Cancer Staging, Particularly in This Era of Treatment De-Escalation.
    AJR Am J Roentgenol. 2023 Apr 26. doi: 10.2214/AJR.23.29501.
    PubMed    
    
    
    
30. LOBBES MBI, Essers BAB
    Cost-Effectiveness of Breast Cancer Staging Modalities: Point-Contrast-Enhanced Mammography as an Alternative to Breast MRI for Preoperative Staging in Patients with Breast Cancer.
    AJR Am J Roentgenol. 2023 Apr 26. doi: 10.2214/AJR.23.29337.
    PubMed    
    
    
    
31. OFFIT LR, Chikarmane SA, Lacson RC, Giess CS, et al
    Frequency and Outcomes of BI-RADS Category 3 Assessments in Patients With a Personal History of Breast Cancer: Full-Field Digital Mammography Versus Digital Breast Tomosynthesis.
    AJR Am J Roentgenol. 2023 Apr 12. doi: 10.2214/AJR.23.29067.
    PubMed     Abstract available
    
    
    
32. MENDELSON EB
    Beyond the AJR: Supplemental Ultrasound Screening Complements Digital Breast Tomosynthesis in Cancer Detection.
    AJR Am J Roentgenol. 2023 Apr 5. doi: 10.2214/AJR.23.29364.
    PubMed    
    
    
    March 2023
33. COVINGTON MF, Hoffman JM, Morton KA, Buckway B, et al
    Prospective Pilot Study of (18)F-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas.
    AJR Am J Roentgenol. 2023 Mar 15. doi: 10.2214/AJR.22.28809.
    PubMed     Abstract available
    
    
    
34. MEMA E, Lane EG, Drotman MB, Eisen CS, et al
    Axillary Lymphadenopathy After a COVID-19 Vaccine Booster Dose: Time to Resolution on Ultrasound Follow-Up and Associated Factors.
    AJR Am J Roentgenol. 2023 Mar 8. doi: 10.2214/AJR.22.28970.
    PubMed     Abstract available
    
    
    
35. BURKE CJ, Schonberger A, Friedman EB, Berman RS, et al
    Image-Guided Radar Reflector Localization for Small Soft-Tissue Lesions in the Musculoskeletal System.
    AJR Am J Roentgenol. 2023;220:399-406.
    PubMed     Abstract available
    
    
    February 2023
36. PIRES-GONCALVES L
    Editorial Comment: Abbreviated MRI for Breast Cancer Neoadjuvant Chemotherapy Response Assessment-One Step Forward in an Important Research Pathway.
    AJR Am J Roentgenol. 2023 Feb 22:9. doi: 10.2214/AJR.23.29167.
    PubMed    
    
    
    
37. CHOU SS
    Editorial Comment: Ultrafast MRI for Ductal Carcinoma In Situ-Potential for Imaging Biomarkers and Abbreviated MRI.
    AJR Am J Roentgenol. 2023 Feb 22:11. doi: 10.2214/AJR.23.29153.
    PubMed    
    
    
    
38. TANG WJ, Chen SY, Hu WK, Li XL, et al
    Abbreviated Versus Full-Protocol MRI for Breast Cancer Neoadjuvant Chemotherapy Response Assessment: Diagnostic Performance by General and Breast Radiologists.
    AJR Am J Roentgenol. 2023 Feb 8. doi: 10.2214/AJR.22.28686.
    PubMed     Abstract available
    
    
    
39. MICELI R, Gao Y, Qian K, Heller SL, et al
    Predicting Upgrade of Ductal Carcinoma in Situ to Invasive Cancer at Breast Surgery With Ultrafast Imaging.
    AJR Am J Roentgenol. 2023 Feb 8. doi: 10.2214/AJR.22.28698.
    PubMed     Abstract available
    
    
    
40. GREENSTEIN JA, Friedewald SM
    Beyond the AJR: Potential Effects of Insurance Coverage Mandates for Digital Breast Tomosynthesis.
    AJR Am J Roentgenol. 2023;220:304.
    PubMed    
    
    
    
41. KORNECKI A, Bhaduri M, Khan N, Nachum IB, et al
    Contrast-Enhanced Mammography-Guided Breast Biopsy: Single Center Experience.
    AJR Am J Roentgenol. 2023 Feb 1. doi: 10.2214/AJR.22.28780.
    PubMed     Abstract available
    
    
    January 2023
42. WANG S, Sun Y, You C, Jiang T, et al
    Association of Clinical Factors and Degree of Early Background Parenchymal Enhancement on Contrast-Enhanced Mammography.
    AJR Am J Roentgenol. 2023 Jan 25. doi: 10.2214/AJR.22.28769.
    PubMed     Abstract available
    
    
    
43. SINHA P, Lamonica DM
    Beyond the AJR: (99m)Tc-MDP Bone Scintigraphy-Has It Met Its Match?
    AJR Am J Roentgenol. 2023 Jan 11. doi: 10.2214/AJR.23.28978.
    PubMed    
    
    
    
44. WANG LC, Philip M, Bhole S, Rao S, et al
    Pathologic Outcomes in Single Versus Multiple Areas of Architectural Distortion on Digital Breast Tomosynthesis.
    AJR Am J Roentgenol. 2023;220:50-62.
    PubMed     Abstract available
    
    
    December 2022
45. SEILER SJ, Neuschler EI, Butler RS, Lavin PT, et al
    Optoacoustic Imaging With Decision Support for Differentiation of Benign and Malignant Breast Masses: A 15-Reader Retrospective Study.
    AJR Am J Roentgenol. 2022 Dec 7. doi: 10.2214/AJR.22.28470.
    PubMed     Abstract available
    
    
    November 2022
46. LEE YS, Cheng YY, Yeh DM
    Factors That May Influence Contrast-Enhanced Digital Mammography Findings.
    AJR Am J Roentgenol. 2022 Nov 30:1. doi: 10.2214/AJR.22.28236.
    PubMed    
    
    
    
47. VAN NIJNATTEN TJA, Lobbes MBI, Cozzi A, Patel BK, et al
    Barriers to Implementation of Contrast-Enhanced Mammography in Clinical Practice: AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2022 Nov 30. doi: 10.2214/AJR.22.28567.
    PubMed     Abstract available
    
    
    
48. MURILLO NDB, Rueda MA, Ortegon JDC
    Contrast-Enhanced Mammography, a Diagnostic and Follow-Up Method With Potential Research Opportunities.
    AJR Am J Roentgenol. 2022 Nov 16:1. doi: 10.2214/AJR.22.28228.
    PubMed    
    
    
    
49. YOON JH, Kim EK
    Beyond the AJR: Deep Learning Model for Risk-Based Breast Cancer Screening.
    AJR Am J Roentgenol. 2022 Nov 9. doi: 10.2214/AJR.22.28703.
    PubMed    
    
    
    
50. WEAVER OO, Yang WT, Scoggins ME, Adrada BE, et al
    Challenging Contrast-Enhanced Mammography-Guided Biopsies: Practical Approach Using Real-Time Multimodality Imaging and a Proposed Procedural Algorithm.
    AJR Am J Roentgenol. 2022 Nov 2. doi: 10.2214/AJR.22.28572.
    PubMed     Abstract available
    
    
    September 2022
51. AHLAWAT S, Debs P, Amini B, Lecouvet FE, et al
    Clinical Applications and Controversies of Whole-Body MRI: AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2022 Sep 28. doi: 10.2214/AJR.22.28229.
    PubMed     Abstract available
    
    
    
52. NGUYEN DL, Boron A, Oluyemi ET, Myers KS, et al
    Comparison of Diagnostic Mammography-Guided Biopsy and Digital Breast Tomosynthesis-Guided Biopsy of Suspicious Breast Calcifications: Results in 1354 Biopsies.
    AJR Am J Roentgenol. 2022 Sep 14. doi: 10.2214/AJR.22.28320.
    PubMed     Abstract available
    
    
    
53. OLUYEMI ET, Ambinder EB
    Beyond the AJR: Racial and Ethnic Disparities in the Timeliness of Biopsy After Abnormal Screening Mammography.
    AJR Am J Roentgenol. 2022 Sep 7. doi: 10.2214/AJR.22.28458.
    PubMed    
    
    
    August 2022
54. LEE CU, Larson NB, Urban MW, Miller AL 2nd, et al
    Factors Associated With Ultrasound Color Doppler Twinkling by Breast Biopsy Markers: In Vitro and Ex Vivo Evaluation of 35 Commercially Available Markers.
    AJR Am J Roentgenol. 2022 Aug 31. doi: 10.2214/AJR.22.28107.
    PubMed     Abstract available
    
    
    
55. NIDA BA, Rooney TB, Miller MM
    Utility of MRI-Directed Contrast-Enhanced Mammography for Biopsy Planning of Suspicious MRI-Detected Breast Lesions.
    AJR Am J Roentgenol. 2022 Aug 24. doi: 10.2214/AJR.22.28055.
    PubMed     Abstract available
    
    
    July 2022
56. HUNT KN, Conners AL, Samreen N, Rhodes D, et al
    PPV of the Molecular Breast Imaging Lexicon.
    AJR Am J Roentgenol. 2022 Jul 20. doi: 10.2214/AJR.21.27047.
    PubMed     Abstract available
    
    
    
57. CHEN JX, Deng F
    Screening Mammography Utilization Among Women With Visual or Hearing Impairment: Results From the 2019 National Health Interview Survey.
    AJR Am J Roentgenol. 2022 Jul 13. doi: 10.2214/AJR.22.27992.
    PubMed     Abstract available
    
    
    
58. DELEAU F, Linck PA, Brouste V, Thomassin-Naggara I, et al
    Impact of Obtaining a Digital Breast Tomosynthesis (DBT) Spot Compression View on Assessment of Equivocal DBT Findings.
    AJR Am J Roentgenol. 2022;219:37-45.
    PubMed     Abstract available
    
    
    
59. VILLA-CAMACHO JC, Bahl M
    Management of Architectural Distortion on Digital Breast Tomosynthesis With Nonmalignant Pathology at Biopsy.
    AJR Am J Roentgenol. 2022;219:46-54.
    PubMed     Abstract available
    
    
    June 2022
60. WOODARD S
    Editorial Comment: Evidence Supporting Contrast-Enhanced Mammography (CEM) for Monitoring Neoadjuvant Chemotherapy Response and Showing the Potential of Delayed CEM.
    AJR Am J Roentgenol. 2022 Jun 29. doi: 10.2214/AJR.22.28128.
    PubMed    
    
    
    
61. BERNARDI D, Vatteroni G, Acquaviva A, Valentini M, et al
    Contrast-Enhanced Mammography Versus MRI in the Evaluation of Neoadjuvant Therapy Response in Patients With Breast Cancer: A Prospective Study.
    AJR Am J Roentgenol. 2022 Jun 22. doi: 10.2214/AJR.22.27756.
    PubMed     Abstract available
    
    
    
62. GONG AJ, Nguyen DL, Lee EE, Mullen LA, et al
    Comparison of Outcomes for One-View Asymmetries Recalled From Digital Breast Tomosynthesis Versus Full-Field Digital Mammography Screening Examinations.
    AJR Am J Roentgenol. 2022 Jun 15. doi: 10.2214/AJR.22.27820.
    PubMed     Abstract available
    
    
    May 2022
63. LAMB LR, Lehman CD, Gastounioti A, Conant EF, et al
    Reply to "The Matrix Is Not Ready for Screening Mammography".
    AJR Am J Roentgenol. 2022 May 25:2-3. doi: 10.2214/AJR.22.27502.
    PubMed    
    
    
    
64. BRENNER RJ
    The Matrix Is Not Ready for Screening Mammography.
    AJR Am J Roentgenol. 2022 May 25:1-2. doi: 10.2214/AJR.22.27423.
    PubMed    
    
    
    
65. BERGMANN LL, Hobbs S
    Beyond the AJR: The Impact of Screening Population in Lung Cancer Overdiagnosis.
    AJR Am J Roentgenol. 2022 May 25. doi: 10.2214/AJR.22.27970.
    PubMed    
    
    
    
66. LANE EG, Eisen CS, Drotman MB, Dodelzon K, et al
    Time for Resolution of COVID-19 Vaccine-Related Lymphadenopathy and Associated Factors.
    AJR Am J Roentgenol. 2022 May 18. doi: 10.2214/AJR.22.27687.
    PubMed     Abstract available
    
    
    
67. LAWSON MB, Herschorn SD, Sprague BL, Buist DSM, et al
    Imaging Surveillance Options for Individuals With a Personal History of Breast Cancer: AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2022 May 11. doi: 10.2214/AJR.22.27635.
    PubMed     Abstract available
    
    
    April 2022
68. DONTCHOS BN, Wang GX
    Beyond the AJR: Impact of Routine Breast Cancer Risk Assessment on Screening Mammography Adherence Among Women in Racial and Ethnic Minority Groups.
    AJR Am J Roentgenol. 2022 Apr 20:1. doi: 10.2214/AJR.21.27107.
    PubMed    
    
    
    
69. LOWRY KP
    Breast Imaging in Older Patients: Counterpoint-Navigating Uncertainty.
    AJR Am J Roentgenol. 2022 Apr 13. doi: 10.2214/AJR.22.27733.
    PubMed    
    
    
    March 2022
70. GUIRGUIS MS, Adrada BE, Scoggins ME, Moseley TW, et al
    The Challenging Image-Guided Preoperative Breast Localization: A Modality-Based Approach.
    AJR Am J Roentgenol. 2022;218:423-434.
    PubMed     Abstract available
    
    
    February 2022
71. LU AH, Zuley ML, Berg WA
    Enhancing Cherry Hemangioma: A Mimic for Breast Cancer on Contrast-Enhanced Mammography.
    AJR Am J Roentgenol. 2022 Feb 9. doi: 10.2214/AJR.22.27363.
    PubMed    
    
    
    
72. MULLEN LA, Ambinder EB
    Beyond the AJR: Validation of an Artificial Intelligence Breast Cancer Risk Assessment Model Across Diverse International Cohorts.
    AJR Am J Roentgenol. 2022 Feb 2. doi: 10.2214/AJR.22.27436.
    PubMed    
    
    
    
73. DESTOUNIS S
    Beyond the AJR: Screening Mammography Over Age 75.
    AJR Am J Roentgenol. 2022 Feb 2. doi: 10.2214/AJR.22.27447.
    PubMed    
    
    
    
74. DONTCHOS BN, Lehman CD
    Reply to "Strategies Used to Reduce the Time of Diagnosis in Screening Mammography".
    AJR Am J Roentgenol. 2022;218:389-390.
    PubMed    
    
    
    January 2022
75. HO EL, Kim MJ, Wilkinson LS, Given-Wilson R, et al
    The Global Reading Room: Recovery of Breast Cancer Screening Services After the COVID-19 Pandemic First Wave.
    AJR Am J Roentgenol. 2022 Jan 26. doi: 10.2214/AJR.22.27416.
    PubMed    
    
    
    
76. KHANANI S
    Editorial Comment: Artificial Intelligence in Mammography-Our New Reality.
    AJR Am J Roentgenol. 2022 Jan 12. doi: 10.2214/AJR.22.27345.
    PubMed    
    
    
    
77. LAMB LR, Lehman CD, Gastounioti A, Conant EF, et al
    Artificial Intelligence (AI) for Screening Mammography, From the AI Special Series on AI Applications.
    AJR Am J Roentgenol. 2022 Jan 12. doi: 10.2214/AJR.21.27071.
    PubMed     Abstract available
    
    
    
78. D'ALESSIO D
    Editorial Comment: Move Forward to Bring Patients Back for Breast Cancer Screening.
    AJR Am J Roentgenol. 2022 Jan 5. doi: 10.2214/AJR.21.27247.
    PubMed    
    
    
    
79. LAMB LR, Bahl M
    Evidence-Based Pragmatic Approach to the Management of Borderline or High-Risk Breast Lesions.
    AJR Am J Roentgenol. 2022;218:186-187.
    PubMed     Abstract available
    
    
    December 2021
80. AMBINDER EB, Myers KS, Oluyemi E, Panigrahi B, et al
    Reply to "Women Successfully Treated for Breast Cancer Can Return Immediately to Annual Screening".
    AJR Am J Roentgenol. 2021 Dec 29:1-2. doi: 10.2214/AJR.21.27061.
    PubMed    
    
    
    
81. KOPANS DB
    Women Successfully Treated for Breast Cancer Can Return Immediately to Annual Screening.
    AJR Am J Roentgenol. 2021 Dec 29:1. doi: 10.2214/AJR.21.27030.
    PubMed    
    
    
    
82. GONZALEZ-GOMEZ S, Rueda-Ruiz N, Palazuelos G
    Strategies Used to Reduce the Time of Diagnosis in Screening Mammography.
    AJR Am J Roentgenol. 2021 Dec 29:1. doi: 10.2214/AJR.21.27042.
    PubMed    
    
    
    
83. HAO M, Edmonds C, Nachiappan A, Conant E, et al
    Management Strategies for Patients Presenting With Symptomatic Lymphadenopathy and Breast Edema After Recent COVID-19 Vaccination.
    AJR Am J Roentgenol. 2021 Dec 29. doi: 10.2214/AJR.21.27118.
    PubMed     Abstract available
    
    
    
84. NARANJO ID, Sogani J, Saccarelli C, Horvat JV, et al
    MRI Screening of BRCA Mutation Carriers: Comparison of Standard Protocol and Abbreviated Protocols With and Without T2-Weighted Images.
    AJR Am J Roentgenol. 2021 Dec 22. doi: 10.2214/AJR.21.27022.
    PubMed     Abstract available
    
    
    
85. NGUYEN DL, Ambinder EB, Myers KS, Mullen LA, et al
    COVID-19 Vaccine-Related Axillary Adenopathy on Breast Imaging: Follow-Up Recommendations and Histopathologic Findings.
    AJR Am J Roentgenol. 2021 Dec 22. doi: 10.2214/AJR.21.27162.
    PubMed     Abstract available
    
    
    
86. POREMBKA JH, Seiler SJ, Sharifi A, Mootz A, et al
    Diagnostic Evaluation of Recalled Noncalcified Lesions Using Ultrasound Alone Versus Ultrasound Plus Additional Mammographic Views: A Prospective Study.
    AJR Am J Roentgenol. 2021 Dec 15. doi: 10.2214/AJR.21.26700.
    PubMed     Abstract available
    
    
    
87. BHATT AA, Woodard GA, Lee CU
    Use of an Introducer for Radioactive Seed Localization of Targets Beyond the Length of Available Preloaded Needles.
    AJR Am J Roentgenol. 2021;217:1475.
    PubMed    
    
    
    
88. LEE SJ, Wahab RA, Sobel LD, Zhang B, et al
    Analysis of 612 Benign Papillomas Diagnosed at Core Biopsy: Rate of Upgrade to Malignancy, Factors Associated With Upgrade, and a Proposal for Selective Surgical Excision.
    AJR Am J Roentgenol. 2021;217:1299-1311.
    PubMed     Abstract available
    
    
    November 2021
89. AMIR T, Hogan MP, Jacobs S, Sevilimedu V, et al
    Comparison of False-Positive Versus True-Positive Findings on Contrast-Enhanced Digital Mammography.
    AJR Am J Roentgenol. 2021 Nov 24. doi: 10.2214/AJR.21.26847.
    PubMed     Abstract available
    
    
    
90. LEHMAN CD, Mercaldo SF, Wang GX, Dontchos BN, et al
    Screening Mammography Recovery After COVID-19 Pandemic-Related Closures: Associations of Facility Access and Racial and Ethnic Screening Disparities.
    AJR Am J Roentgenol. 2021 Nov 24. doi: 10.2214/AJR.21.26890.
    PubMed     Abstract available
    
    
    October 2021
91. SADIGH G, Lowry KP
    Beyond the AJR: Screening Breast MRI Is Associated With Substantial Financial Burden in Women With Private Insurance Due to Lack of Coverage by the Affordable Care Act.
    AJR Am J Roentgenol. 2021 Oct 20:1. doi: 10.2214/AJR.21.26956.
    PubMed    
    
    
    
92. CARNAHAN MB, Pockaj B, Pizzitola V, Giurescu ME, et al
    Contrast-Enhanced Mammography for Newly Diagnosed Breast Cancer in Women With Breast Augmentation: Preliminary Findings.
    AJR Am J Roentgenol. 2021;217:855-856.
    PubMed     Abstract available
    
    
    
93. AMBINDER EB, Plotkin A, Euhus D, Mullen LA, et al
    Tomosynthesis-Guided Vacuum-Assisted Breast Biopsy of Architectural Distortion Without a Sonographic Correlate: A Retrospective Review.
    AJR Am J Roentgenol. 2021;217:845-854.
    PubMed     Abstract available
    
    
    
94. CHUNG HL, Sun J, Leung JWT
    Breast Cancer Skip Metastases: Frequency, Associated Tumor Characteristics, and Role of Staging Nodal Ultrasound in Detection.
    AJR Am J Roentgenol. 2021;217:835-844.
    PubMed     Abstract available
    
    
    September 2021
95. VIERS KN, Hunt LD
    Lymph Node Staging in Newly Diagnosed Breast Cancer: Point-Preoperative Staging Axillary Ultrasound is Valuable in the Contemporary Evaluation of Newly Diagnosed Breast Cancer.
    AJR Am J Roentgenol. 2021 Sep 29. doi: 10.2214/AJR.21.26812.
    PubMed    
    
    
    
96. BHOLE S, Friedewald SM
    Lymph Node Staging in Newly Diagnosed Breast Cancer: Counterpoint-Sentinel Biopsy Surpasses Axillary Imaging in Early-Stage Cancers, But Is the Sun Setting on This Controversy?
    AJR Am J Roentgenol. 2021 Sep 29. doi: 10.2214/AJR.21.26767.
    PubMed    
    
    
    
97. WOLFSON S, Heller SL, Gao Y
    Multiple Bilateral Circumscribed Masses (MBCM) at Screening Breast Ultrasound (US): Outcomes of New or Enlarging Masses at Follow-up.
    AJR Am J Roentgenol. 2021 Sep 22. doi: 10.2214/AJR.21.26520.
    PubMed     Abstract available
    
    
    
98. SANDERS LM
    Editorial Comment: MRI is Useful in a High-Risk Patient Cohort Prior to Prophylactic Mastectomy, Obviating Sentinel Node Sampling in Those with Negative Studies.
    AJR Am J Roentgenol. 2021 Sep 15. doi: 10.2214/AJR.21.26795.
    PubMed    
    
    
    
99. OLUYEMI E
    Editorial Comment: Offering Immediate Screening Mammography Interpretation May Be an Effective way to Reduce the Racial and Ethnic Disparity Gap in the Time to Diagnostic Follow-up.
    AJR Am J Roentgenol. 2021 Sep 15. doi: 10.2214/AJR.21.26798.
    PubMed    
    
    
    
100. TALIAFERRO AS, Price ER, Hayward JH, Wong J, et al
     Utility and Outcomes of Pre-Operative Screening Breast MRI for Planned Bilateral Prophylactic Mastectomy in High-Risk Patients.
     AJR Am J Roentgenol. 2021 Sep 15. doi: 10.2214/AJR.21.26561.
     PubMed     Abstract available
     
     
     August 2021
101. YOON JH, Kim EK, Kim GR, Han K, et al
     Mammographic Surveillance After Breast Conserving Therapy: Impact of Digital Breast Tomosynthesis and Artificial Intelligence-Based Computer-Aided Detection.
     AJR Am J Roentgenol. 2021 Aug 11. doi: 10.2214/AJR.21.26506.
     PubMed     Abstract available
     
     
     
102. GRIMM LJ, Mango VL, Harvey JA, Plecha DM, et al
     Implementation of Abbreviated Breast MRI for Screening: AJR Expert Panel Narrative Review.
     AJR Am J Roentgenol. 2021 Aug 11. doi: 10.2214/AJR.21.26349.
     PubMed     Abstract available
     
     
     July 2021
103. CHUNG HL, Tso HH, Middleton LP, Sun J, et al
     Axillary Nodal Metastases in Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma: Comparison of Node Detection and Morphology by Ultrasound.
     AJR Am J Roentgenol. 2021 Jul 28. doi: 10.2214/AJR.21.26135.
     PubMed     Abstract available
     
     
     
104. BARR RG, DeSivestri A, Golatta M
     Outcomes of Return to Routine Screening for BI-RADS 3 Lesions Detected at Supplemental Automated Whole-Breast Ultrasound in Women with Dense Breasts: A Prospective Study.
     AJR Am J Roentgenol. 2021 Jul 14. doi: 10.2214/AJR.21.26180.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.